Member Info for Doc.Daneeka

Doc83 making the most sense on this. It can't be 1 or 2 - surely even Synairgen cd not be this incompetent or cavalier. So 3 it must be. And most of the reasons for ' They couldn't ' are positive. So let's suspend judgement for a while longer.

We'll know within a month. Ticker tape parade to Trafalgar Sq- or Southgate will be gone

No doubt that he's in the last chance saloon though. One last chance to put right the last 2 failures and succeed - or he'll be gone before the end of the summer. Promise, and limited success just don't cut it when you're playing for such high stakes.

We're definitely waiting for "TRIALS"

Interim report "Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral “shedders”, a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024. "

Marcin Mankowski CMO RNS "Marcin’s in-depth knowledge of the Company and SNG001 as well as his strong track record in leading the strategy, design and implementation of global clinical development programmes, will be invaluable to us as we prepare to enter further clinical trials of SNG001.”

Joseph Colliver RNS "Joseph Colliver, newly appointed CFO of Synairgen, commented: “This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001.

We also do NOT know that the delays are down to regulatory approval. It might be this - but the key line might be "Subject to this preparatory work... and the company is still not ready. This is much more likely than a hold-up by regulators for tiny trials in specifically targeted populations with a drug that has an unblemished safety record over many years. If they still intend to test SNG in ventilated patients that might be slower but again - it'll be highly targeted even in this population and as you know SNG likes a fire to put out and is effective well into the cytokine storm. There will be no shortage of volunteers and for many of them it'll be the last throw of the dice.

Of course it's June 4th 2021 isn't it !! I can't even think straight. !!

Gosh fellas - I had the most awful dream. The company failed the P3 - and sp had crashed to 6 and a half p, with just a few million in the bank. Proper nightmare - but phew what a relief to wake up. Always enjoy this debate - and as I've said many times, I'm not selling for less than £10 a share. Even then I'd probs stick with it as Synairgen becomes the next Biontech, and just live off the dividends. Posting this and then gonna fix the wonky date on my pc - which says it's June 4th 2024 hahaha !!! Lost 2 years while I was asleep hahaha !!!

Meltonboy - just stick him in the bin.

Still just time - but I don't think anyone expects it now. We're also past the latest date ever for full year results - which probably doesn't mean anything but could be good ( if they're delaying to add a clinical update ) or bad ( for any number of other reasons)

The only NDAs they're currently constrained by are the ones for Not Doing Anything & No Dosing Anticipated & Need Dosh Advance.

Thanks Brand - do you have a view on how this might influence the mini P2 design - assuming they had this before the final designs were set ? The conclusion is that it merits further investigation in a large trial, and particularly that further data is needed to prove or disprove the signals that secondary bacterial infections were improved in the SNG group ( they lacked the required samples needed to explore this properly ) and also that a positive RSV test showed the greatest area of interest in terms of viral clearance. Can the mini P2 (s) test any of this properly - or does this data feed into the large platform trial that will follow success at this stage.

Once they get to that point I guess it's possible they can have different inclusion criteria for the different RVIs under investigation.

Have they ever had a closed door AGM Wigster ? Apart from during the pandemic I mean... Doc83 mentioned this possibility a while back and it seemed at the time that it would be exceedingly poor form if they couldn't bring themselves to face the shareholders properly at least once a year. Is it common in AIM, and are there other - less suspicious - reasons why they might choose not to front up. ? I guess if they were in the final dot-crossing stage of a deal they might prefer to greet their adoring public virtually.

Double green :) Not peeping but it's either a double team special or 2 x FnV or 2 x Td. This time of night - the odds are on double Fruits. He works the night shift in between trips to the little boys room.

They still just about have time to start the P2s in H1 - SG016 was announced and underway in 2 weeks, Sprinter in a month. But most of us feel they've already missed the window, Clearly now - if I may offer an answer to Elsol's question - a start in H2 with assistance and funding from a bigger partner is preferable, and not just preferable but actually the only way the company can proceed ( having said in September 2023 that the cash runway would last for "at least" another year. It can't last much longer and these trials, even if they get underway in a month or two - will not now report until well into 2025 ) They might limp through to LPD before funds are exhausted - but they'd do better to cut a deal now when there's still a few quid in the bank and when the partnership would help them to power the small trials to their maximum potential.

Just imagine if we discover the P2s didn't make it because they had 30 and not 40 patients, or if the assays they used weren't best in class.

They will have finally given up hope of finishing the project themselves and keeping all the cash - it's just a shame they didn't get someone competent on board between SG016 and Sprinter.

Putting you and Fruiits finally and forever into the bin. Your tag team defence of the indefensible will never stop.

And before I delete you - you should know that I'm still invested - rather than being employed to be here. Coming up for 4 years. That I still think there's a place for this drug - depsite RM and PM's worst efforts ( you can't blame the founders they did this work decades ago and handed it over ) And that I hope to meet some of the really good guys for a beer when we're finally done and hopefully raise a glass to the competent company that takes this through to completion. I doubt we'll get much from it - but those who were brave enough to average down should be ok. We all came here to start with because we believed in it at a dark time and even though those clouds have passed and the drug we hoped would play a significant part failed to do so, there will still be a need for it somewhere. Hopefully not just for intubated >85 yr olds with several comorbs and auto antibodies for Ifn.

You'll be off to your next project long before then anyway, and I wish you well with it. Hope they send you someone as relentless as Fruits for the bag work.

Tommy they were designing a trial that would start in early 2021. At the time they started thinking about the design, every newspaper in the world and every news bulletin was full of reports of the accelerated programmes that would deliver the vaccines in record time. 23 Vaccine candidates were in trials or in preparation for trials before SG016 delivered. Before the Sprinter trial began 3 Vaccines were approved and millions of doses were going into arms all over the world. Before Sprinter was a month old ALL of the aged and vulnerable in the UK were protected. 15 million of them.

It was as predictable and obvious as the 20% reduction in mortality shown for Dexa in RECOVERY - which you also regard as a Who KNEW WTF ? event.

For a bright boy you seem to be struggling badly with this one. Plenty to defend the company on - as your every post demonstrates - but to suggest the company wasn't negligent in failing to recognise that the world would be wildly altered by the time Sprinter started dosing betrays a one eyed dedication to the cause that leaves the rest of us speechless.

You're not this stupid - but you ARE on someone's payroll. Never seen until the shi.t hit the fan and never not seen, since.

"Agree. Now that DocDan and Joey's accusation that the company was incompetent has been proven to be thoroughly incorrect, we can indeed move on."

Keep digging that grave Fruits. As far as incompetence goes, this is world class. We know Synairgen didn't collect a single drop of blood or sputum or snot in their defining once in a lifetime trial. Nada from hundreds of patients in modern efficient hospitals. ( unless there's a few old margarine tubs of flob in the fridge that they haven't told us about)

And is now scratching around looking for data from a generic trial in which SNG did not feature.

Surprising really from a company which once boasted of its world class respiratory Biobank Platform and trumpeted how crucial these samples were in the work they were doing. I can't even find the Biobanks on the site now - but I'm sure Tommy will find it somewhere.

Tommy you and Fruits are the only revisionistas.

Dexa - Remdes...in hospitals ??? Who Knew !!

Vaxes - excuse me - they work ??? Who knew !!

Samples - we really did ask for them and nobody managed to collect any. What can you do and Who Knew !!

It was all an act of god. !! Who Knew !!

You're both coming apart at the seams. Night now. I'll leave it to you to decide who reports this post and gets it taken down.

Ball park figure will do - 200 ? 300 ? And where is that blood work ? Safe and sound in the famed Synairgen biobank I'm sure.

Fair enough if it really wasn't feasible to collect samples in some hospitals under particular stress - maybe some of the more remote sites on the world tour - but how many samples from Sprinter patients did they manage to harvest in total ?

This is the protocol I said they'd use months ago. Confirmed RVI - Age and Co-morbidities - with a side order of AABs. We were hoping for something flash and new but the reality is the only thing they can really screen for is Auto-abs. And they can only do that if they've got a fast enough assay turnaround. It's why PM is standing next to his little poster in San Diego and it's essentially what we've known for 2 years. After all that Tommyd guff about SNG being held back because science hadn't caught up with it.

the point you make about there being no evidence of AABs affecting mortality is troubling. I read another piece that hypothesised that by the time the effect was most noticeable the patients were already too sick for the impact to be gauged.

There is already at ;least one large and definitive study for AAB -Ifns Joey. You canmaybe say they need to see if AABs for Ifns affect the other RVIs they're interested in, but it's very unlikely anything in UNIVERSAL will be better than what's already known for Covid from much larger samples and using the same cutting edge assays.

https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-022-01095-5